Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation

Haematologica

Volumn 94, Issue 11, 2009, Pages 1613-1617

  Bornhäuser, Martin ^a   Oelschlaegel, Uta ^a   Platzbecker, Uwe ^a   Bug, Gesine ^b   Lutterbeck, Karin ^a   Kiehl, Michael G ^c   Schetelig, Johannes ^a   Kiani, Alexander ^a   Illmer, Thomas ^a   Schaich, Markus ^a   Theuser, Catrin ^a   Mohr, Brigitte ^a   Brendel, Cornelia ^d   Fauser, Axel A ^c   Klein, Stefan ^b   Martin, Hans ^b   Ehninger, Gerhard ^a   Thiede, Christian ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Medizinische Klinik II   (United States)

^c Bone Marrow Transplantation Clinic   (United States)

^d Universitätskilinikum Gießen and Marburg   (Germany)

Author keywords

Allogeneic stem cell transplantation; CD34+; Cell sorting; Donor chimerism; Leukemia; Relapse

Indexed keywords

CD34 ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RISK; CANCER SURVIVAL; CHIMERA; CONTROLLED STUDY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PROGNOSIS; RECURRENT DISEASE;

ANTIGENS, CD34; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 70449432763     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.007765     Document Type: Article

References (20)

1. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007;110:1379-1387 (Pubitemid 47281440)
2. Tavernier E, Boiron JM, Huguet F, Bradstock K, Vey N, Kovacsovics T, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007;21:1907-1914 (Pubitemid 47299963)
3. Platzbecker U, Thiede C, Freiberg- Richter J, Helwig A, Mohr B, Prange G, et al. Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GMCSF. Ann Hematol 2001;80:144-149 (Pubitemid 32266153)
4. Schmid C, Schleuning M, Aschan J, Ringden O, Hahn J, Holler E, et al. Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 2004;18:1430-1433 (Pubitemid 39136755)
5. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reducedintensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5675-5687 (Pubitemid 46300164)
6. Kern W, Haferlach C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008;112:4-16.
7. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-1704 (Pubitemid 36237562)
8. van Leeuwen JE, van Tol MJ, Bodzinga BG, Wijnen JT, van der KM, Joosten AM, et al. Detection of mixed chimaerism in flow-sorted cell subpopulations by PCR-amplified VNTR markers after allogeneic bone marrow transplantation. Br J Haematol 1991;79:218-225
9. Baurmann H, Nagel S, Binder T, Neubauer A, Siegert W, Huhn D. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Blood 1998;92:3582-3590 (Pubitemid 28525183)
10. Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O. Leukemia lineage- specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001;15:1976-1985 (Pubitemid 33115007)
11. Scheffold C, Kroeger M, Zuehlsdorf M, Tchinda J, Silling G, Bisping G, et al. Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis. Leukemia 2004;18:2048-2050 (Pubitemid 40028436)
12. Thiede C, Bornhauser M, Oelschlagel U, Brendel C, Leo R, Daxberger H, et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001;15:293-302. (Pubitemid 32175467)
13. Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999;23:1055-1060 (Pubitemid 29250852)
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-462
15. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997;16:901-910
16. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kroger N. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Exp Hematol 2009;37:135-142
17. Zeiser R, Spyridonidis A, Wäsch R, Ihorst G, Grüllich C, Bertz H, et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia 2005;19:814-821 (Pubitemid 40663102)
18. Platzbecker U, Mohr B, von BM, Binder M, Schetelig J, Ehninger G, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007;21:2384-2385
19. Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res 2007;31:257-259 (Pubitemid 44854182)
20. Stone RM, Deangelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60. (Pubitemid 40053063)